Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination

Sarah Frey; Caoilfhionn M. Connolly; Teresa Po Yu Chiang; Mayan Teles; Jennifer L. Alejo; Brian J. Boyarsky; Lisa Christopher-Stine; William A. Werbel; Dorry L. Segev; Julie J. Paik

doi:10.1016/S2665-9913(21)00282-4

Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination

Sarah Frey, Caoilfhionn M. Connolly, Teresa Po Yu Chiang, Mayan Teles, Jennifer L. Alejo, Brian J. Boyarsky, Lisa Christopher-Stine, William A. Werbel, Dorry L. Segev, Julie J. Paik

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	e753-e754
Journal	The Lancet Rheumatology
Volume	3
Issue number	11
DOIs	https://doi.org/10.1016/S2665-9913(21)00282-4
State	Published - Nov 2021

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.1016/S2665-9913(21)00282-4

Cite this

@article{0059da6adc274ee9ab2585003f4cb600,

title = "Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination",

author = "Sarah Frey and Connolly, {Caoilfhionn M.} and Chiang, {Teresa Po Yu} and Mayan Teles and Alejo, {Jennifer L.} and Boyarsky, {Brian J.} and Lisa Christopher-Stine and Werbel, {William A.} and Segev, {Dorry L.} and Paik, {Julie J.}",

note = "Funding Information: All authors contributed to the creation of this manuscript in all aspects including data gathering, analysis, writing, and critical revision. DLS reports consulting and speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallincrodt, and Thermo Fisher Scientific. LC-S reports consultant fees from Janssen, Boehringer-Ingelheim, Mallinckrodt, EMD-Serono, Allogene, Roivant, Octapharma, and ArgenX. All other authors report no competing interests. This research was made possible with the generous support of the Ben-Dov family. This work was supported by grant number 5T32DK007713 (JLA) and F32DK124941 (BJB) from the National Institute of Diabetes and Digestive and Kidney Diseases; K24AI144954 (DLS) from the National Institute of Allergy and Infectious Diseases; and K23AR073927 (JJP) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The analyses described here are the responsibility of the authors alone and do not necessarily reflect the views or policies of the US Department of Health and Human Services, nor does mention of trade names, commercial products or organisations imply endorsement by the US Government. ",

year = "2021",

month = nov,

doi = "10.1016/S2665-9913(21)00282-4",

language = "English (US)",

volume = "3",

pages = "e753--e754",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Lancet Publishing Group",

number = "11",

}

TY - JOUR

T1 - Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination

AU - Frey, Sarah

AU - Connolly, Caoilfhionn M.

AU - Chiang, Teresa Po Yu

AU - Teles, Mayan

AU - Alejo, Jennifer L.

AU - Boyarsky, Brian J.

AU - Christopher-Stine, Lisa

AU - Werbel, William A.

AU - Segev, Dorry L.

AU - Paik, Julie J.

N1 - Funding Information: All authors contributed to the creation of this manuscript in all aspects including data gathering, analysis, writing, and critical revision. DLS reports consulting and speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallincrodt, and Thermo Fisher Scientific. LC-S reports consultant fees from Janssen, Boehringer-Ingelheim, Mallinckrodt, EMD-Serono, Allogene, Roivant, Octapharma, and ArgenX. All other authors report no competing interests. This research was made possible with the generous support of the Ben-Dov family. This work was supported by grant number 5T32DK007713 (JLA) and F32DK124941 (BJB) from the National Institute of Diabetes and Digestive and Kidney Diseases; K24AI144954 (DLS) from the National Institute of Allergy and Infectious Diseases; and K23AR073927 (JJP) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The analyses described here are the responsibility of the authors alone and do not necessarily reflect the views or policies of the US Department of Health and Human Services, nor does mention of trade names, commercial products or organisations imply endorsement by the US Government.

PY - 2021/11

Y1 - 2021/11

UR - http://www.scopus.com/inward/record.url?scp=85117933053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85117933053&partnerID=8YFLogxK

U2 - 10.1016/S2665-9913(21)00282-4

DO - 10.1016/S2665-9913(21)00282-4

M3 - Letter

AN - SCOPUS:85117933053

VL - 3

SP - e753-e754

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

SN - 2665-9913

IS - 11

ER -

Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this